Fact or Fiction? Test Your Knowledge on Assessment and Management Strategies in Tardive Dyskinesia

This activity has been designed to meet the educational needs of psychiatrists and neurologists as well as advanced practice psychiatry and neurology clinicians involved in the care of patients with tardive dyskinesia (TD).

Supported by an educational grant from:

Neurocrine Biosciences, Inc.

Activity Information

Release date: July 31, 2019
Valid through: July 31, 2020
Estimated time to complete activity: 90 minutes
Media: Internet

Statement of Need/Program Overview

At any given time, roughly one-quarter of individuals taking antipsychotics experience TD, a condition characterized by involuntary movements of the face and body. Moreover, as the use of antipsychotics has expanded to disorders such as depression, behavioral disorders, and dementia, TD is no longer primarily limited to patients with schizophrenia. TD has an outsized impact on patients’ ability to carry out daily tasks and interact with others. However, because TD has long been considered an irreversible consequence of the use of antipsychotics or other dopamine receptor–blocking agents, many clinicians have come to view it with a sort of “therapeutic nihilism.” As a result, many patients have not received treatment for their TD. Recently, the US FDA approved 2 medications, both vesicular monoamine transporter 2 (VMAT2) inhibitors, to treat TD, giving patients access to the first well-tolerated oral treatments shown to be effective for this condition. To ensure that patients receive maximum benefit from this advance in TD treatment, clinicians must learn how to integrate VMAT2 inhibitors into their practice. In this activity, an expert faculty member will dispel common myths about TD, educating clinicians about how to recognize and diagnose TD promptly, how VMAT2 inhibitors work to improve TD symptoms, how the 2 approved agents differ, and how VMAT2 inhibitors can be used alongside other strategies to improve outcomes for patients with TD.   

Learning Goal/Purpose

The goal of this enduring activity is to enhance the knowledge and competence clinicians need to integrate VMAT2 inhibitors into their practice, thus expanding the array of treatment choices available to patients with TD and ultimately improving their lives.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Demonstrate knowledge of the TD assessment and diagnosis process
  • Use knowledge of the differences in VMAT2 inhibitors’ molecular structures to explain differences in their safety profiles and dosing
  • Formulate a treatment plan tailored to the needs of a patient with TD

Faculty

Leslie L. Citrome, MD, MPH
Clinical Professor of Psychiatry & Behavioral Sciences
New York Medical College
Valhalla, New York

Physician Credit

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and CMEology. MER is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Medical Education Resources designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This CE activity provides 1.5 contact hours of continuing nursing education.  Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299.

Disclosure of Conflicts of Interest

Medical Education Resources (MER) ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality activities that promote improvements or quality in health care and not the business interest of a commercial interest.

The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:


Leslie L. Citrome, MD, MPH
Reported Financial Relationships
Grants/Research Support from Acadia, Alkermes, Allergan, Impel, Indivior, Intra-Cellular Therapeutics, Janssen, Lundbeck, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva, Vanda; Consulting for Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Shire, Sunovion, Takeda, Teva; Ownership Interest/Shareholder of Stocks (small number of shares of common stock): Bristol-Myers Squibb, Eli Lilly, Johnson & Johnson, Merck, Pfizer purchased > 10 years ago; Royalty/Patent Holder for Wiley (Editor-in-Chief, International Journal of Clinical Practice), UpToDate (reviewer), Springer Healthcare (book)

The content managers reported the following financial relationships with commercial interests whose products or services may be mentioned in this activity:

Rob Lowney (CMEology)
No financial relationships to disclose.

Dana Ravyn, PhD, MPH (CMEology)
No financial relationships to disclose.

Beth Goodwin (CMEology)
No financial relationships to disclose.

MER content reviewers
No financial relationships to disclose.

Method of Participation

There are no fees for participating in and receiving credit for this activity. During the period TBD through TBD, participants must 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest by recording the best answer to each question, and 4) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better, with no more than 3 attempts.

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, CMEology, and/or Neurocrine Biosciences, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Fee Information

There is no fee for this educational activity.

MER Privacy Policy

Medical Education Resources maintains high standards for the protection of privacy over the Internet. The purpose of this statement is to explain what information we obtain, how it is used, and how visitors can restrict its use or disclosure.
 
The only information MER obtains is information supplied voluntarily by the visitor.
 
We do not sell or disclose individually identifiable information obtained online unless it is required by law or disclosure is necessary to protect the safety of customers, employees, or property.
 
We use the information to grade your posttest and to send you a certificate of completion of the activity. If we use a third-party company to grade your posttest and issue certificates of completion, we will give the information to that company for that purpose only.
 
For each activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
 
We may use the information to invite you to participate in other activities that we may offer.
 
Medical Education Resources is committed to safeguarding customer privacy, and we require our employees to protect the privacy of information about our customers. Should you wish to delete your information from our files or discuss our privacy policy, please contact us (800-421-3756).

For questions about this activity, please contact CMEology at: info@cmeology.org.